Pharma: Page 33
-
iStock via Getty Images
Tips for tackling trial recruitment and retention woes in oncology
How new tools are helping companies find and keep cancer patients in clinical studies.
By Kelly Bilodeau • Oct. 31, 2022 -
Leon Neal via Getty Images
Vaccine chief’s exit spurs new slate of GSK executive changes
How the pharma giant is consolidating power as it looks to become a dominant force in the vaccine market.
By Karissa Waddick • Oct. 31, 2022 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Stock via Getty Images
OpinionPharma execs on creating a better workplace culture
Top women execs speak to the leadership skills they are embracing as the industry adjusts to a new normal.
By Taren Grom • Oct. 28, 2022 -
Permission granted by Biogen
Riches, rags, riches: Is Biogen the Cinderella of biotechs?
Biogen and Eisai's new Alzheimer's drug is wowing investigators, and it might help the companies get past previous failures.
By Michael Gibney • Oct. 27, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Ironwood Pharmaceuticals’ Diane Stroehmann
The VP of regulatory affairs and global patient safety explains why her line of work lets her do “a little of everything,” and the company’s plans to score a new approval for its blockbuster drug.
By Taren Grom • Oct. 26, 2022 -
Justin Sullivan/Staff via Getty Images
Q&ANobel Prize winner Carolyn Bertozzi on revealing the power of chemistry in drug development
The Stanford researcher and biotech entrepreneur discusses how click and bioorthogonal chemistry could revolutionize drug development.
By Karissa Waddick • Oct. 26, 2022 -
Permission granted by Doug Langa
Backed by celebrity interest, Novo is finding new success in weight loss — while staying true to its roots
The company's head of U.S. and Canadian operations explains how it’s evolving its game plan after 100 years in the insulin space.
By Meagan Parrish • Oct. 25, 2022 -
Jackfoto via Getty Images
Biosimilars will gain ground in 2023 with Humira launches — and that’s just the beginning
In Amgen's 2022 Biosimilars Trend Report, the company tracks the progress and potential of the copycat drugs as they reach a pivotal moment.
By Michael Gibney • Oct. 24, 2022 -
Stock via Getty Images
OpinionWhat’s keeping pharma leaders up at night
C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.
By Taren Grom • Oct. 21, 2022 -
Mario Tama via Getty Images
J&J reveals just how much economic turbulence is affecting Big Pharma
The healthcare giant showed pharmaceutical gains, but that's no thanks to the economic environment of persistent inflation and a strong U.S. dollar.
By Michael Gibney • Oct. 20, 2022 -
Stock via Getty Images
5 impactful drug trial failures from the last year
Major recent trial flops and what they mean for companies, patients and the industry.
By Meagan Parrish • Oct. 19, 2022 -
Alex Wong via Getty Images
Think your company could be on HHS’ drug price negotiation list? Here’s how to navigate next steps
Know what to expect from the CMS over the next few months as it implements the drug reforms laid out in the Inflation Reduction Act.
By Karissa Waddick • Oct. 18, 2022 -
Stock via Getty Images
A new class of drugs with ‘huge’ potential in the fight against challenging breast cancers
Drug developers have been making headway in treating the most difficult and deadly forms of breast cancer.
By Kelly Bilodeau • Oct. 18, 2022 -
Stock via Getty Images
The Novartis U.S. Foundation’s president on the ‘magical piece’ of its 10-year health equity plan
Dr. Patrice Matchaba discusses Novartis’ end-to-end approach to tackling systemic health disparities.
By Meagan Parrish • Oct. 17, 2022 -
Permission granted by BMS / Ryan Moslin
Q&AHe helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma
Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.
By Michael Gibney • Oct. 17, 2022 -
Stock via Getty Images
OpinionWhat’s your leadership brand?
Pharma industry leaders share their brand personas.
By Taren Grom • Oct. 14, 2022 -
iStock via Getty Images
Q&A // First 90 DaysComing out of stealth, RIGImmune aims to catch up with ever-mutating viruses
President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.
By Kelly Bilodeau • Oct. 13, 2022 -
iStock via Getty Images
Robotic pills could open a world of possibilities for the biologics market
As the oral biologic market heats up, Rani Therapeutics is looking to dominate the field with its robotic pill for treatment of chronic conditions.
By Karissa Waddick • Oct. 13, 2022 -
Permission granted by Ameet Mallik
Q&AWhere the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology
The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.
By Meagan Parrish • Oct. 12, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: HBA’s Nikki Jones
As the Healthcare Businesswomen’s Association’s first chief people and DEI officer, Jones is poised to tackle pay gap inequity, systemic gender bias and leadership barriers impeding women of color.
By Taren Grom • Oct. 12, 2022 -
iStock via Getty Images
The digital therapeutics revolution is happening and Big Pharma is buying in — with caution
Companies like Pfizer, Novartis, Sanofi and BMS are diving into the world of digital therapeutics while recognizing the limitations of the young field.
By Michael Gibney • Oct. 10, 2022 -
Permission granted by GoodRx
Sponsored by GoodRxBeyond buzzwords: Making a practice of diversity, equity and inclusion
Watch Dr. Preeti Parikh, executive medical director at GoodRx, explain how she sees parallels between her mother’s challenges to promote health equity as a physician, and current diversity, equity, and inclusion (DE&I) challenges in the workplace.
Oct. 10, 2022 -
Stock via Getty Images
OpinionAre you a bad boss?
Pharma execs share their tips for being a better leader.
By Taren Grom • Oct. 7, 2022 -
Permission granted by Asia Kepka
Q&AHer antibiotic company failed. Now she’s helping others avoid the same fate.
The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.
By Karissa Waddick • Oct. 6, 2022 -
iStock via Getty Images
Making MovesC-suite shake-ups at 23andMe, Moderna signal new stages of growth
With their latest personnel moves, these life sciences companies are preparing for major business shifts.
By Karissa Waddick • Oct. 5, 2022
Previous
